Potential new therapies for MS (CAR-T cells, BTKIs, HSCT, remyelination, high dose b-cell depleters) and the newly understood pathophysiology of MS. From UCSF. pubmed.ncbi.nlm.nih.gov/40474602/
June 11, 2025 at 4:57 AM
Potential new therapies for MS (CAR-T cells, BTKIs, HSCT, remyelination, high dose b-cell depleters) and the newly understood pathophysiology of MS. From UCSF. pubmed.ncbi.nlm.nih.gov/40474602/
Bruton tyrosine kinase inhibitors (#BTKis) appeared to offset the adverse prognostic impact of #NOTCH1 mutations in chronic lymphocytic leukemia (#CLL). Study in European Journal of Haematology.
Read more: https://bit.ly/4gTTqam
#RareDisease #Leukemia #Hematology #Oncology #OncSky #RareSky
Read more: https://bit.ly/4gTTqam
#RareDisease #Leukemia #Hematology #Oncology #OncSky #RareSky
BTK Inhibitors Overcome Poor Prognosis of CLL With NOTCH1 Mutations
BTKis neutralized the adverse prognostic effect of NOTCH1 mutations in chronic lymphocytic leukemia (CLL), a study found.
bit.ly
October 6, 2025 at 3:00 PM
Bruton tyrosine kinase inhibitors (#BTKis) appeared to offset the adverse prognostic impact of #NOTCH1 mutations in chronic lymphocytic leukemia (#CLL). Study in European Journal of Haematology.
Read more: https://bit.ly/4gTTqam
#RareDisease #Leukemia #Hematology #Oncology #OncSky #RareSky
Read more: https://bit.ly/4gTTqam
#RareDisease #Leukemia #Hematology #Oncology #OncSky #RareSky
Glad to see more options, but BTKIs aren’t without ꜱᴇʀɪᴏᴜꜱ side effects.
December 15, 2024 at 1:20 PM
Glad to see more options, but BTKIs aren’t without ꜱᴇʀɪᴏᴜꜱ side effects.
An NMA of BTKis found zanubrutinib to be the most efficacious treatment for patients with high-risk R/R CLL. buff.ly/IXmt44Y #hemesky
June 27, 2025 at 5:05 PM
An NMA of BTKis found zanubrutinib to be the most efficacious treatment for patients with high-risk R/R CLL. buff.ly/IXmt44Y #hemesky
Bruton Tyrosine Kinase inhibitors (BTKis) have emerged as promising oral agents targeting both B cells and microglia. Tolebrutinib and Evobrutini showed good safety and efficacy profiles in treating relapsing multiple sclerosis. Nasophar...
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #MedSky
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #MedSky
Multiple sclerosis updates and the safety and efficacy of Bruton tyrosine kinase inhibitors in it: A systematic review
Bruton Tyrosine Kinase inhibitors (BTKis) have emerged as promising oral agents targeting both B cells and microglia. Tolebrutinib and Evobrutini showed good safety and efficacy profiles in treating r
gregory-ms.com
September 28, 2025 at 7:10 AM
Bruton Tyrosine Kinase inhibitors (BTKis) have emerged as promising oral agents targeting both B cells and microglia. Tolebrutinib and Evobrutini showed good safety and efficacy profiles in treating relapsing multiple sclerosis. Nasophar...
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #MedSky
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #MedSky
Aging in MS and treatment options with Dr. Bianca Weinstock-Guttman @MSViewsandNews. Metformin, BTKis, foralumab, CAR-T. remyelination. paramagnetic rim lesions, memory problems. youtu.be/ibcVKu5Z1zk?...
Aging in MS and treatment options
YouTube video by The MS Views and News Learning Channel
youtu.be
July 14, 2025 at 8:08 PM
Aging in MS and treatment options with Dr. Bianca Weinstock-Guttman @MSViewsandNews. Metformin, BTKis, foralumab, CAR-T. remyelination. paramagnetic rim lesions, memory problems. youtu.be/ibcVKu5Z1zk?...
TKIs and BTK inhibitors are targeted therapies that shut down key signaling pathways cancer cells rely on for survival. Each class blocks different kinase “switches,” shaping how they’re used across solid tumors & blood cancers. My latest lesson highlights how they work.
youtu.be/NJXt-CVtrvA
youtu.be/NJXt-CVtrvA
TKIs vs BTKIs in Cancer Treatment
YouTube video by Dr. Rob Swanda
youtu.be
September 14, 2026 at 3:17 PM
TKIs and BTK inhibitors are targeted therapies that shut down key signaling pathways cancer cells rely on for survival. Each class blocks different kinase “switches,” shaping how they’re used across solid tumors & blood cancers. My latest lesson highlights how they work.
youtu.be/NJXt-CVtrvA
youtu.be/NJXt-CVtrvA
Agreed on all counts, including big concerns about the stats. Primarily looking forward to what we’ll learn from the results regardless of whether any BTKis are viable options.
February 5, 2026 at 6:28 PM
Agreed on all counts, including big concerns about the stats. Primarily looking forward to what we’ll learn from the results regardless of whether any BTKis are viable options.
📑 New ESMO CPG on Lymphomas
✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis
www.annalsofoncology.org/article/S092...
✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis
www.annalsofoncology.org/article/S092...
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
The treatment landscape for many lymphoma entities continues to evolve rapidly, with
multiple recent approvals of novel non-chemotherapy (ChT)-based approaches. The following
Clinical Practice Guideli...
www.annalsofoncology.org
September 12, 2025 at 10:41 PM
📑 New ESMO CPG on Lymphomas
✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis
www.annalsofoncology.org/article/S092...
✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis
www.annalsofoncology.org/article/S092...
Dr. Dreyling's algorithm for management of fit MCL. Tricky part is lack of ibrutinib availability in this setting, but many of us have been using 2nd-gen BTKis. #lymsm #18ICML @icmlugano.bsky.social
June 18, 2025 at 9:18 AM
Dr. Dreyling's algorithm for management of fit MCL. Tricky part is lack of ibrutinib availability in this setting, but many of us have been using 2nd-gen BTKis. #lymsm #18ICML @icmlugano.bsky.social
This recent Blood Cancer Discovery study identified and characterized PKCβ as a therapeutic target in CLL, including CLL resistant to BTKis.
👉 Read the full study: BTKi-Resistant CLL Is Sensitive to PKCβ Inhibitors buff.ly/yMECG3s
👉 Read the full study: BTKi-Resistant CLL Is Sensitive to PKCβ Inhibitors buff.ly/yMECG3s
January 26, 2026 at 10:43 PM
This recent Blood Cancer Discovery study identified and characterized PKCβ as a therapeutic target in CLL, including CLL resistant to BTKis.
👉 Read the full study: BTKi-Resistant CLL Is Sensitive to PKCβ Inhibitors buff.ly/yMECG3s
👉 Read the full study: BTKi-Resistant CLL Is Sensitive to PKCβ Inhibitors buff.ly/yMECG3s
A 72-year-old with CLL developed fatal necrotizing fasciitis from Lichtheimia spp after 4 months on zanubrutinib. Literature review found 8 cases of BTKi-associated mucormycosis, 37.5% mortality. 🦠💔##idsky
Skin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review
AbstractBruton tyrosine kinase inhibitors (BTKis) have been associated with an increased risk of invasive fungal disease, with skin and soft tissue mucormycosis accounting for a minority of cases. We present a 72-year-old patient with chronic lymphocytic leukemia who developed necrotizing fasciitis and myositis due to Lichtheimia spp after 4 months of therapy with the second-generation BTKi zanubrutinib, with a fatal outcome despite aggressive treatment. Our literature review identified 7 additional cases of BTKi-associated skin and soft tissue mucormycosis, revealing an all-cause mortality rate of 37.5%. Two-thirds of the patients had a previous trauma or skin lesion.
academic.oup.com
November 29, 2025 at 12:30 AM
A 72-year-old with CLL developed fatal necrotizing fasciitis from Lichtheimia spp after 4 months on zanubrutinib. Literature review found 8 cases of BTKi-associated mucormycosis, 37.5% mortality. 🦠💔##idsky
ICYMI in our July issue: a Review of Bruton's tyrosine kinase (BTK) inhibitors for multiple sclerosis (MS), including their different pharmacological properties, clinical trial results, and potential for use in MS clinical practice www.thelancet.com/journals/lan...
Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics
Bruton's tyrosine kinase (BTK) is an intracellular enzyme involved in a wide range
of cellular functions. BTK inhibitors (BTKIs) are of interest in multiple sclerosis
because they modulate various typ...
www.thelancet.com
July 9, 2026 at 7:01 AM
ICYMI in our July issue: a Review of Bruton's tyrosine kinase (BTK) inhibitors for multiple sclerosis (MS), including their different pharmacological properties, clinical trial results, and potential for use in MS clinical practice www.thelancet.com/journals/lan...
In our July issue: a Review discusses the rationale for development of Bruton's tyrosine kinase (BTK) inhibitors in multiple sclerosis (MS), differences in their pharmacological properties, results from clinical trials, and potential for use in MS clinical practice www.thelancet.com/journals/lan...
Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics
Bruton's tyrosine kinase (BTK) is an intracellular enzyme involved in a wide range
of cellular functions. BTK inhibitors (BTKIs) are of interest in multiple sclerosis
because they modulate various typ...
www.thelancet.com
June 29, 2026 at 8:13 AM
In our July issue: a Review discusses the rationale for development of Bruton's tyrosine kinase (BTK) inhibitors in multiple sclerosis (MS), differences in their pharmacological properties, results from clinical trials, and potential for use in MS clinical practice www.thelancet.com/journals/lan...
Want to hear about the targeting of BTK for the treatment of CLL and NHL?
Then don't forget to watch our fantastic roundtable discussion with experts Tanya Siddiqi, Krish Patel & Alexey Danilov!
Click here:
👉https://buff.ly/4f3mR7s👈
#iwNHL24 #LYMsm #CLLsm #NonHodgkinLymphoma
Then don't forget to watch our fantastic roundtable discussion with experts Tanya Siddiqi, Krish Patel & Alexey Danilov!
Click here:
👉https://buff.ly/4f3mR7s👈
#iwNHL24 #LYMsm #CLLsm #NonHodgkinLymphoma
Targeting BTK to treat CLL and NHL: insights from BTKis and novel BTK degraders | VJHemOnc
In this video, Tanya Siddiqi, MD, City of Hope, Duarte, CA, Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, and...
buff.ly
December 7, 2024 at 11:00 AM
Want to hear about the targeting of BTK for the treatment of CLL and NHL?
Then don't forget to watch our fantastic roundtable discussion with experts Tanya Siddiqi, Krish Patel & Alexey Danilov!
Click here:
👉https://buff.ly/4f3mR7s👈
#iwNHL24 #LYMsm #CLLsm #NonHodgkinLymphoma
Then don't forget to watch our fantastic roundtable discussion with experts Tanya Siddiqi, Krish Patel & Alexey Danilov!
Click here:
👉https://buff.ly/4f3mR7s👈
#iwNHL24 #LYMsm #CLLsm #NonHodgkinLymphoma
Development, validation, and clinical application of LC-MS/MS method for simultaneous determination of ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, and their active metabolites in patients with B-cell lymphoma #ABC link.springer.com/article/10.1...
Development, validation, and clinical application of LC-MS/MS method for simultaneous determination of ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, and their active metabolites in patients w...
Bruton’s tyrosine kinase inhibitors (BTKis) exhibit significant interindividual pharmacokinetics, making therapeutic drug monitoring (TDM) a promising approach for personalized therapy. However, simul...
link.springer.com
December 20, 2024 at 7:16 PM
Development, validation, and clinical application of LC-MS/MS method for simultaneous determination of ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, and their active metabolites in patients with B-cell lymphoma #ABC link.springer.com/article/10.1...
Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics www.sciencedirect.com/science/arti... #hvhebron #nimm
Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics
Bruton's tyrosine kinase (BTK) is an intracellular enzyme involved in a wide range of cellular functions. BTK inhibitors (BTKIs) are of interest in mu…
www.sciencedirect.com
June 19, 2026 at 11:17 AM
Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics www.sciencedirect.com/science/arti... #hvhebron #nimm
Tycel J. Phillips, MD, of @cityofhope.bsky.social elucidates the research landscape of BTKis in #MCL, particularly its potential as a first-line treatment.
https://bit.ly/3ZiPcRy
#MantleCellLymphoma #lymsm
https://bit.ly/3ZiPcRy
#MantleCellLymphoma #lymsm
BTK Inhibitor Therapy Makes Inroads Into First-Line MCL
BTK inhibitors (BTKi) in mantle cell lymphoma (MCL) are examined by Tycel J. Phillips, MD, particularly as potential first-line therapy.
bit.ly
January 16, 2026 at 11:05 PM
Tycel J. Phillips, MD, of @cityofhope.bsky.social elucidates the research landscape of BTKis in #MCL, particularly its potential as a first-line treatment.
https://bit.ly/3ZiPcRy
#MantleCellLymphoma #lymsm
https://bit.ly/3ZiPcRy
#MantleCellLymphoma #lymsm
The GOlDiLOX trial is investigating the combination of pirtobrutinib + glofitamab in #MantleCellLymphoma that progresses after covalent BTKis.🩸
Want to learn more? Watch our interview with @drmikedickinson.bsky.social from #EHA2025:
🎥 buff.ly/FL2519k
#LYMsm #CTSM #BloodSky #HemeSky #TrialUpdate
Want to learn more? Watch our interview with @drmikedickinson.bsky.social from #EHA2025:
🎥 buff.ly/FL2519k
#LYMsm #CTSM #BloodSky #HemeSky #TrialUpdate
June 24, 2025 at 3:04 PM
The GOlDiLOX trial is investigating the combination of pirtobrutinib + glofitamab in #MantleCellLymphoma that progresses after covalent BTKis.🩸
Want to learn more? Watch our interview with @drmikedickinson.bsky.social from #EHA2025:
🎥 buff.ly/FL2519k
#LYMsm #CTSM #BloodSky #HemeSky #TrialUpdate
Want to learn more? Watch our interview with @drmikedickinson.bsky.social from #EHA2025:
🎥 buff.ly/FL2519k
#LYMsm #CTSM #BloodSky #HemeSky #TrialUpdate
En el mundo real, la discontinuación temprana es más común en los pacientes que inician un BTKi que los que inician venetoclax con obinutuzumab, con una mayor tasa de hospitalización #venetoclax #BTKIs #CLL ascopubs.org/doi/full/10....
Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia | JCO Oncology Practice
PURPOSEVenetoclax and Bruton's tyrosine kinase inhibitors (BTKis) are key treatment options
for patients with chronic lymphocytic leukemia (CLL) in the frontline setting. This
study characterized post...
ascopubs.org
August 15, 2025 at 8:25 AM
En el mundo real, la discontinuación temprana es más común en los pacientes que inician un BTKi que los que inician venetoclax con obinutuzumab, con una mayor tasa de hospitalización #venetoclax #BTKIs #CLL ascopubs.org/doi/full/10....
This interactive learning article, supported by #BeOneMedicines, provides an overview of the available #BTKIs for the treatment of B-cell malignancies to support pharmacists with their use in practice
#cancercare #cancertreatment #pharmacy
#cancercare #cancertreatment #pharmacy
Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists
Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK…
buff.ly
October 17, 2025 at 5:30 PM
This interactive learning article, supported by #BeOneMedicines, provides an overview of the available #BTKIs for the treatment of B-cell malignancies to support pharmacists with their use in practice
#cancercare #cancertreatment #pharmacy
#cancercare #cancertreatment #pharmacy
This interactive learning article, supported by #BeOneMedicines, provides an overview of the available #BTKIs for the treatment of B-cell malignancies to support pharmacists with their use in practice
#cancercare #cancertreatment #pharmacy
#cancercare #cancertreatment #pharmacy
Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists
Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK…
buff.ly
October 9, 2025 at 5:30 PM
This interactive learning article, supported by #BeOneMedicines, provides an overview of the available #BTKIs for the treatment of B-cell malignancies to support pharmacists with their use in practice
#cancercare #cancertreatment #pharmacy
#cancercare #cancertreatment #pharmacy
This interactive learning article, supported by #BeOneMedicines, provides an overview of the available Bruton tyrosine kinase inhibitors for the treatment of B-cell malignancies to support pharmacists with their use in practice
#BTKIs #cancercare #cancertreatment #pharmacy
#BTKIs #cancercare #cancertreatment #pharmacy
Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists
Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK…
buff.ly
October 6, 2025 at 5:30 PM
This interactive learning article, supported by #BeOneMedicines, provides an overview of the available Bruton tyrosine kinase inhibitors for the treatment of B-cell malignancies to support pharmacists with their use in practice
#BTKIs #cancercare #cancertreatment #pharmacy
#BTKIs #cancercare #cancertreatment #pharmacy
3/7 It's always good to see longer-term data for these agents, especially in this population. For patients who've developed resistance or intolerance to covalent BTKis, having an alternative mechanism of action like this non-covalent inhibitor is clearly a useful option.
May 4, 2026 at 7:01 AM
3/7 It's always good to see longer-term data for these agents, especially in this population. For patients who've developed resistance or intolerance to covalent BTKis, having an alternative mechanism of action like this non-covalent inhibitor is clearly a useful option.